Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : MDNA save search
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study
Published: 2024-04-10 (Crawled : 13:00) - biospace.com/
MDNAF | $1.24 -17.54% 67K
|
n/a
|
| O: 18.35%
H: 13.64%
C: 12.4%
mdna11 ongoing expansion results study
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
Published: 2024-04-10 (Crawled : 11:00) - globenewswire.com
MDNAF | $1.24 -17.54% 67K
|
n/a
|
| O: 18.35%
H: 13.64%
C: 12.4%
mdna11 association cancer ongoing expansion research for meeting results study
Medicenna Presents Updated Results of Single Agent MDNA11 Anti-tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
Published: 2024-04-09 (Crawled : 21:00) - globenewswire.com
MDNAF | $1.24 -17.54% 67K
|
n/a
|
| O: 18.35%
H: 13.64%
C: 12.4%
mdna11 association cancer ongoing expansion research for meeting results study
Medicenna Presents Updated Preclinical Data on MDNA113, a First-in-Class, Targeted and Masked Bi-functional anti-PD1-IL2 Superkine, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR)
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
MDNAF | $1.24 -17.54% 67K
|
n/a
|
| O: -3.82%
H: 0.0%
C: -13.49%
mdna113 association cancer research preclinical for meeting
Medicenna to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Published: 2024-04-04 (Crawled : 11:00) - globenewswire.com
MDNAF | $1.24 -17.54% 67K
|
n/a
|
| O: -4.01%
H: 9.01%
C: -3.43%
conference
Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting
Published: 2024-03-06 (Crawled : 12:00) - globenewswire.com
MDNAF | $1.24 -17.54% 67K
|
n/a
|
| O: 3.0%
H: 6.12%
C: 0.36%
mdna11 association update cancer research meeting trial
Medicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate Update
Published: 2024-02-14 (Crawled : 12:30) - globenewswire.com
MDNAF | $1.24 -17.54% 67K
|
n/a
|
| O: 2.95%
H: 29.02%
C: 23.53%
update therapeutics financial results
Medicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
Published: 2024-02-13 (Crawled : 12:00) - globenewswire.com
MDNAF | $1.24 -17.54% 67K
|
n/a
|
| O: 2.04%
H: 2.8%
C: -0.92%
mdna11 keytruda first tumors advanced study
Medicenna Announces Appointment of New Auditor
Published: 2024-01-12 (Crawled : 23:00) - globenewswire.com
MDNAF | $1.24 -17.54% 67K
|
n/a
| Email alert
Add to watchlist
MDNA | $0.157 -0.32% 1.3M
|
Health Technology
| Email alert
Add to watchlist
Medicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with Pembrolizumab
Published: 2024-01-09 (Crawled : 12:00) - globenewswire.com
MDNAF | $1.24 -17.54% 67K
|
n/a
|
| O: 1.69%
H: 3.03%
C: -3.03%
mdna11 study
Medicenna Extends Period to Exercise Certain Warrants - December 22, 2023
Published: 2023-12-22 (Crawled : 06:00) - biospace.com/
MDNAF | $1.24 -17.54% 67K
|
n/a
|
| O: -1.41%
H: 9.08%
C: 1.96%
Medicenna Extends Period to Exercise Certain Warrants
Published: 2023-12-22 (Crawled : 00:00) - globenewswire.com
MDNAF | $1.24 -17.54% 67K
|
n/a
|
| O: -1.41%
H: 9.08%
C: 1.96%
Medicenna Announces Trading on the OTCQB Under the Symbol MDNAF
Published: 2023-12-19 (Crawled : 12:00) - globenewswire.com
MDNAF | $1.24 -17.54% 67K
|
n/a
|
| O: 2.3%
H: 4.74%
C: -3.85%
otcqb
Delisting of Securities of Genesis Growth Tech Acquisition Corp.; Financial Strategies Acquisition Corp.; Kiromic BioPharma, Inc.; Infinity Pharmaceuticals, Inc.; Molekule Group, Inc.; EBET, Inc.; Shift Technologies, Inc.; Ontrak, Inc.; RVL Pharmaceuticals plc; Biocept, Inc.; Akumin Inc.; Appreciate Holdings, Inc.; Liberty TripAdvisor Holdings, Inc.; Tempo Automation Holdings, Inc.; Medicenna Therapeutics Corp.; RiceBran Technologies; and Acer Therapeutics Inc. from The Nasdaq Stock Market
Published: 2023-11-17 (Crawled : 21:00) - globenewswire.com
FXCO | $11.0 0.91% 2.7K
|
n/a
| Email alert
Add to watchlist
INFI | $0.016 12.5% 1.1M
|
Health Technology
| Email alert
Add to watchlist
LTRPA | $1.37 5.37% 80K
|
Consumer Services
| Email alert
Add to watchlist
NDAQ | $60.35 0.47% 0.46% 3.1M
|
Finance
| Email alert
Add to watchlist
AKU | $0.2887 -0.42% 8.5M
|
Health Services
| Email alert
Add to watchlist
MDNA | $0.157 -0.32% 1.3M
|
Health Technology
| Email alert
Add to watchlist
MDNAF | $1.24 -17.54% 67K
|
n/a
| Email alert
Add to watchlist
BIOC | $0.4349 -10.32% 750K
|
Health Services
| Email alert
Add to watchlist
RIBT 4 | $0.17 -12.78% 1.2K
|
Consumer Non-Durables
| Email alert
Add to watchlist
OTRK 4 | $0.2524 -8.08% -8.8% 1.8M
|
Health Services
| Email alert
Add to watchlist
LTRPB | $10.5 -27.62% 53K
|
Consumer Services
| Email alert
Add to watchlist
RVLP | $0.0282 -20.92% 64M
|
Manufacturing
| Email alert
Add to watchlist
ACER | $0.9 -3.61% 420K
|
Health Technology
| Email alert
Add to watchlist
INFIQ | $0.0001 3000.0% 680
|
Manufacturing
| Email alert
Add to watchlist
SFT | $0.1703 -23.66% 180M
|
Finance
| Email alert
Add to watchlist
KRBP | $2.5 -90.21% 830
|
Health Technology
| Email alert
Add to watchlist
GGAA | $21.57 2.1M
|
n/a
| Email alert
Add to watchlist
tempo acquisition pharmaceuticals liberty therapeutics financial growth market
Medicenna Announces Compelling Survival Benefit from Phase 2b Study of Bizaxofusp in Recurrent Glioblastoma at the 28th Annual Meeting of the Society for NeuroOncology
Published: 2023-11-17 (Crawled : 12:00) - globenewswire.com
MDNAF | $1.24 -17.54% 67K
|
n/a
|
| O: -0.44%
H: 4.43%
C: -11.25%
meeting glioblastoma study
Medicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational Highlights
Published: 2023-11-14 (Crawled : 13:30) - globenewswire.com
MDNAF | $1.24 -17.54% 67K
|
n/a
|
| O: 6.2%
H: 2.06%
C: -5.84%
therapeutics financial results
Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual Meeting
Published: 2023-11-09 (Crawled : 14:00) - globenewswire.com
MDNA | $0.157 -0.32% 1.3M
|
Health Technology
| Email alert
Add to watchlist
year meeting glioblastoma
Medicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Published: 2023-11-06 (Crawled : 12:00) - globenewswire.com
MDNA | $0.157 -0.32% 1.3M
|
Health Technology
| Email alert
Add to watchlist
mdna11 durability cancer immunotherapy meeting response study
Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Published: 2023-11-03 (Crawled : 16:00) - globenewswire.com
MDNA | $0.157 -0.32% 1.3M
|
Health Technology
| Email alert
Add to watchlist
mdna113 cancer preclinical immunotherapy meeting
Medicenna Announces Nasdaq Delisting and Cutback of Management Team
Published: 2023-10-27 (Crawled : 12:00) - globenewswire.com
MDNA | $0.157 -0.32% 1.3M
|
Health Technology
|
| O: -11.14%
H: 3.32%
C: -11.37%
management nasdaq
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.